Labeling, affinity, mechanism

The third mechanism that results in slow binding behavior is covalent inactivation of the enzyme by affinity labeling or mechanism-based inhibition (Scheme... 

Despite the mechanistic differences in the definitions of kimcl and A) between quiescent affinity labels and mechanism-based inactivators, the dependence of kohs on [/] is the same for both mechanism. Hence we cannot determine whether or not a compound is acting as a mechanism-based inhibitor, based merely on this two-step kinetic behavior. However, there is a set of distinguishing features of mechanism-based inactivation that are experimentally testable. Compounds that display all of these features can be safely defined as mechanism-based inactivators. 

There are, however, many substances other than physiological substrates which exhibit specific interactions with the active site of enzymes. They include small, synthetic competitive inhibitor molecules, synthetic quasi-substrates, affinity labeling reagents, mechanism-based inhibitors, and so on. This may suggest that these substances can act, because enzymes exhibit some structural allowance in substrate recognition. These specific compounds are expected to be of great value for application in basic research and also in the medicinal field. Some of these specific compounds have reached clinical uses. 

This article describes various approaches to inhibition of enzyme catalysis. Reversible inhibition includes competitive, uncompetitive, mixed inhibition, noncompetitive inhibition, transition state, and slow tight-binding inhibition. Irreversible inhibition approaches include affinity labeling and mechanism-based enzyme inhibition. The kinetics of the various inhibition approaches are summarized, and examples of each type of Inhibition are presented. 

L Irreversible inactivation. Inactivation by affinity labels leads to irreversible covalent bond formation between the enzyme and the inhibitor. Unlike the complex between and enzyme and a rapid, reversible inhibitor, the covalent enzyme-inhibitor complex is no longer in equilibrium with free enzyme and inhibitor. Therefore, exhaustive dialysis or gel filtration of the covalent enzyme-inhibitor complex cannot lead to the recovery of free, active enzyme. However, such experiments do not allow distinction among tight-binding, noncovalent inhibitors, affinity labels, and mechanism-based inactivators. 

Substrate protection. Ligands of the enzyme, either substrates or reversible inhibitors, should greatly decrease the rate of modification by the affinity label. Both affinity labels and mechanism-based inhibitors should be active-site directed, thereby competing with the substrate for the same binding site on the enzyme. This can be tested by incubating the enzyme with increasing amounts of substrate at constant inhibitor concentrations. As the substrate concentration is increased, the rate of inactivation will become slower because, under initial velocity conditions, a portion of the... 

Criteria for the Study of Mechanism-Based Inactivators. In addition to the requirements described above for an affinity label, a mechanism-based inhibitor should also demonstrate the following ... 

As may be expected, criteria for the study of pseudo irreversible inhibitors are very similar to those for both affinity labels and mechanism-based inhibitors. However, because of the inherent reversibility of pseudoirrevers-ible inhibitors, it may be more difficult to obtain structural evidence for the covalent enzyme inhibitor adduct. Further, determination of the rate of reactivation and characterization of the products of the recovery process will also be of major importance in designating an inhibitor as pseudoirreversible. 

The best definition of the third type of irreversible enzyme inhibitor, mechanism-based inactivators, is provided by Dr Richard Silverman, a leading authority on the subject. A mechanism-based inactivator (sometimes, much to my dismay, called a suicide substrate), he writes, is an unreactive compound that has a structural similarity to a substrate or product for an enzyme. Once at the active site of the enzyme, it is converted into a species that generally forms a covalent bond to the enzyme, producing inactivation. Although both quiescent affinity labels and mechanism-based inactivators can be mistaken for... 

Affinity Labels. Active site-directed, irreversible inhibitors or affinity labels are usually substrate analogues that contain a reactive electrophilic functional group. In the first step, they bind to the active site of the target enzyme in a reversible fashion. Subsequentiy, an active site nucleophile in close proximity reacts with the electrophilic group on the substrate to form a covalent bond between the enzyme and the inhibitor, typically via S 2 alkylation or acylation. Affinity labels do not require activation by the catalysis of the enzyme, as in the case of a mechanism-based inhibitor. 

A/-(2,3-Epoxypropyl)-A/-amidinoglycine [70363-44-9] (21) was shown to be an affinity label of creatine kinase. Its mechanism of covalent bond formation is outlined as follows ... 

After release there must be some way of terminating the action of a NT necessitating the presence of an appropriate enzyme and/or uptake mechanism. Such uptake processes can be quite specific chemically. Thus a high-affinity uptake (activated by low concentrations) can be found for glycine in the cord where it is believed to be a NT, but not in the cortex where is has no such action. This specific uptake can be utilised to map terminals for a particular NT, especially if it can be labelled, and also for loading nerves with labelled NT for release studies. 

Figure 8.2 Mechanisms of irreversible enzyme inactivation. (A) Nonspecific affinity labeling, (B) quiescent affinity labeling, and (C) mechanism-based inactivation.

Depending on the mechanism of irreversible reaction, inactivation can appear to proceed through either a single-step or a two-step mechanism (Figure 8.2). In the case of nonspecific affinity labels (see Section 8.2) many amino acid residues on the enzyme molecule, and on other protein molecules in the sample, can be covalently modified by the affinity label. Not every modification event will lead to inactiva-... 

The value of kohs for this type of mechanism is a saturable function of [/], as was the case for quiescent affinity labels (vide supra). For this mechanism, kima (as defined above) is a complex mixture of rate constants ... 

In the kinetic scheme of Figure 8.2C, we see that once the active species is formed, it can go on to inactivate the enzyme directly or be released into solution. If the active species formed is a good affinity label (i.e., is highly electrophilic), there is a chance that this species will rebind and inactivate the enzyme as an affinity label. To be classified as a mechanism-based inactivator, the active species must be demonstrated to directly inactivate the enzyme while still bound, without reliance on dissociation from the EA complex. 

The partitioning of the activated inhibitor between direct covalent inactivation of the enzyme and release into solution is an important issue for mechanism-based inactivators. The partition ratio is of value as a quantitative measure of inactivation efficiency, as described above. This value is also important in assessing the suitability of a compound as a drug for clinical use. If the partition ratio is high, this means that a significant proportion of the activated inhibitor molecules is not sequestered as a covalent adduct with the target enzyme but instead is released into solution. Once released, the compound can diffuse away to covalently modify other proteins within the cell, tissue, or systemic circulation. This could then lead to the same types of potential clinical liabilities that were discussed earlier in this chapter in the context of affinity labels, and would therefore erode the potential therapeutic index for such a compound. 

After more than a decade of use, bupropion (24) is considered a safe and effective antidepressant, suitable for use as first-line treatment. In addition, it is approved for smoking cessation and seasonal affective disorder. It is also prescribed off-label to treat the sexual dysfunction induced by SSRIs. Bupropion is often referred to as an atypical antidepressant and has much lower affinity for the monoamine transporters compared with other monoamine reuptake inhibitors. The mechanism of action of bupropion is still uncertain but may be related to inhibition of dopamine and norepinephrine reuptake transporters as a result of active metabolites [71,72]. In a recently reported clinical trial, bupropion extended release (XL) had a sexual tolerability profile significantly better than that of escitalopram with similar re-... 

Suicide substrates and quiescent affinity labels, unlike the other types of inhibitors discussed in this chapter, form covalent bonds with active site nucleophiles and thereby irreversibly inactivate their target enzymes. A suicide substrate,191 also described by Silverman in a comprehensive review1101 as a mechanism-based inactivator, is a molecule that resembles its target enzyme s true substrate but contains a latent (relatively unreactive) electrophile. When the target enzyme attempts to turn over the... 

---